Skip to main content

EyePoint Pharmaceuticals’ stock soars 212% after company announces positive data for macular degeneration treatment

EyePoint's stock is on track for its biggest ever one-day percentage gain in heavy volume.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.